Biomarkers Predictive of Therapeutic Benefit 1

• 1008 · PDF KRAS G12C抑制剂MK-1084对携带KRAS G12突变肿瘤参与者循环肿瘤DNA水平的影响 Effect of the KRAS G12C inhibitor MK-1084 on circulating tumor DNA levels in participants with KRAS G12-mutated tumors Carlos Rojas, Matteo Simonelli, Adrian Sacher, Mehmet Ali Sendur, Rafal Dziadziuszko, Joon Oh Park, Victor Moreno Garcia, Jair Bar, Yun Fan, Mustafa Erman, Shun Lu, Jenny H. Lee, Rosalyn A. Juergens, Bangwei Cao, Cai Chen, Razvan Cristescu, Thomas Jemielita, Yewon Sofia Choi, Mark D. Ayers, Iwona Lugowska
• 1009 · PDF 在430,467例泛肿瘤组织样本中具有既定和新兴临床可操作性的纯合拷贝数（CN）缺失图谱 Landscape of homozygous copy number (CN) losses with established and emerging clinical actionability across 430,467 pan-tumor tissue samples Timothy A. Yap, Jessica K. Lee, Xin Liu, Erica Gornstein, Amaya Gasco, Richard S. P. Huang, Alexa B. Schrock
• 1010 · PDF DNA水平的复杂融合与RNA表达高度不一致：一项115例中国病例的验证研究 DNA-level complex fusions show high discordance with RNA expression: A validation study of 115 Chinese cases Xinyue Wang, Lu Zhang, Xinyan Li, He Jiang, Jiayi Zhao, Richeng Jiang
• 1011 · PDF 线粒体自噬相关基因表达与CALGB（Alliance）/SWOG 80405入组的转移性结直肠癌患者临床结局的相关性 Correlation of mitophagy related genes expression and clinical outcome in metastatic colorectal cancer patients enrolled in CALGB (Alliance)/SWOG 80405 Shivani Soni, Yan Yang, Michela Bartolini, Pooja Mittal, Fang-Shu Ou, Lesly Torres-Gonzalez, Unnati Hemant Shah, Jae Ho Lo, Steve Soto Trujillo, Yitzhar Goretsky, Wu Zhang, Alan P. Venook, Sandra Algaze, Joshua Millstein, Heinz-Josef Lenz
• 1012 · PDF 检测MTAP纯合缺失的多组学方法可实现从血液样本高灵敏度检测 Multi-omic method to detect MTAP homozygous deletions enables high sensitivity detection from blood samples Geethika Yalamanchili, Sean Gordon, Evan Warner, Shile Zhang, Keelia Clemens, Matthew Ellis, Vishnu Ramani, Marisa Juntilla, Martina Lefterova, Justin Odegaard, Darya Chudova
• 1013 1013 免疫微环境驱动的11q13扩增肝细胞癌免疫治疗耐药 Immune microenvironment driven immunotherapy resistance in 11q13-amplified hepatocellular carcinoma Weiping Zhu
• 1014 · PDF 多模态AI从临床可获得的输入和全切片图像预测免疫检查点抑制剂反应，并提供可解释的肿瘤生物学及联合治疗见解 Multimodal AI predicts immune checkpoint inhibitor response from clinically available inputs and whole-slide images with explainable tumor biology and combination therapy insights Felicia Kuperwaser, Sunil Kumar, Sepideh Foroutan, Dillon Tracy, Kevin Freisen, Taylor Wood, Zong Miao, Nathaniel Tann, Fahad Khan, Jean Michel Rouly, Anshu Jain, Jeff Sherman, Emily Vucic, Maayan Baron
• 1015 · PDF 定量c-MET免疫组化揭示乳头状肾细胞癌的预后亚组 Quantitative c-MET immunohistochemistry reveals prognostic subgroups in papillary renal cell carcinoma Yong Il Lee, Jamin Park, Sun Young Yoon, Yong Mee Cho, Inkeun Park, Bokyung Ahn
• 1016 · PDF PHIT评分整合肿瘤生物学以预测PDAC预后和治疗反应 PHIT score integrates tumor biology to predict PDAC prognosis and therapy response Derek Erstad, Alejandro Zulbaran y Rojas, Christy Chai, Eugene Choi, George Van Buren, E. Ramsay Camp, William E. Fisher, Natalie Vokes
• 1017 · PDF STAT5A启动子高甲基化作为cfDNA液体活检中鳞状细胞癌免疫检查点抑制剂反应的生物标志物 STAT5A promoter hypermethylation as a biomarker of immune checkpoint inhibitor response in squamous cell carcinoma in cfDNA liquid biopsies Janice Patterson, Brooke Overstreet, Jiemin Liao
• 1018 · PDF 纵向外周血TCR追踪预测免疫检查点抑制剂反应 Longitudinal peripheral blood TCR tracking predicts response to immune checkpoint inhibitors Dingyuan Wang, Kaiyan Xu, Parker J. Li, David J. H. Shih, Matthew K. L. Chiu, Jason W. H. Wong, Wei Dai, Aya El Helali
• 1020 · PDF 通过全面的表观基因组液体活检表征功能性雌激素受体（ER）依赖性可对转移性乳腺癌（MBC）内分泌治疗（ET）反应者进行分层 Characterization of functional estrogen receptor (ER) dependence via comprehensive epigenomic liquid biopsy stratifies endocrine therapy (ET) responders with metastatic breast cancer (MBC) Stefania Morganti, Jonathan Beagan, Ningxuan (Shirley) Zhou, Khoi Nguyen, Kalie Smith, Ashka Patel, Catherine Stever, Katheryn Santos, Molly Skeffington, Olivia D'Amico, Travis Clark, Justin Finkle, Anthony D'Ippolito, Mike Zhong, Jamey Guess, Kristian Cibulskis, Aparna Gorthi, Tyrone Tamakloe, Charlene O'Brien, Baovy Tran, Mary McGillicuddy, Nabihah Tayob, Sara M. Tolaney, Nancy U. Lin, Hillary Heiling, Corrie A. Painter, Matthew L. Eaton, J. Carl Barrett, Heather A. Parsons
• 1021 · PDF 通过对非典型肿瘤进行全面基因组分析发现罕见的基因组融合 Detection of rare genomic fusions revealed through comprehensive genomic profiling of atypical tumors Jennifer B. Jackson, Stanislav Fridland, Behtash G. Nezami, Gunja Pathak, Jennifer Dickey, Lawrence Jennings
• 1022 · PDF NFKBIA扩增减弱NKX2.1扩增型肺腺癌中B2M的表达，提示免疫逃逸潜能 NFKBIA amplification attenuates B2M expression in NKX2.1-amplified lung adenocarcinoma, indicating immune evasion potential Ka Yee Li, Anthony J. Iafrate
• 1023 · PDF ER阳性/HER2阴性乳腺癌新辅助来曲唑和ribociclib治疗期间的Ki67动力学及肿瘤生物学转变：来自NEOLETRIB试验的见解 Ki67-kinetics and tumor biology shifts during neoadjuvant letrozole and ribociclib in ER-pos./HER2-neg. breast cancer: Insights from the NEOLETRIB-trial Julius Johannes Grindahl Hettich, Kamilla Fjermeros, Stephanie Beate Geisler, Manouchehr Seyedzadeh, Xavier Tekpli, Vessela N. Kristensen, Elin Edda Seland Agustsdottir, Unn-Cathrin Edvardsen Buvarp, Marie Fongaard, Tatiana Bosnjak-Olsen, Oeyvind Sundby, Alina Carmen Porojnicu, Helle Kristine Skjerven, Tone Hovda, Kristine Kleivi Sahlberg, Andliena Tahiri, Torben Lüders, Lilly Anne Torland, Silje Mathiassen, Sofie Flovik Ranestad, John Christopher Noone, Elma Bahonjic Hönigsperger, Clara Hammarstrøm, Jürgen Geisler
• 1024 · PDF CIN标签作为药物敏感性的生物标志物：来自DNA靶向测序数据的真实世界证据 CIN signatures as biomarkers of drug sensitivity: Real-world evidence from DNA targeted sequencing data David Gómez-Sánchez, Adam Price, Max Schmidt, Sharafudeen Abubakar, Farheen Shah, Christina Lee, Chin-Tung Chen, Barbara Hernando, Daniel Muldoon, Areej Alsaafin, Evan Seffar, George Li, Subhiksha Nandakumar, Wassim Abida, Stephen Graves, Mackenzie Sullivan, Rachel N. Grisham, Britta Weigelt, Luc GT Morris, Nadeem Riaz, Pedram Razavi, Allison L. Richards, Mark Donoghue, Walid Khaled Chatila, Chaitanya Bandlamudi, Nikolaus Schultz, Michael F. Berger, Sohrab Shah, Geoff Macintyre, Julio Garcia-Aguilar, Francisco Sanchez-Vega
• 1025 · PDF 监测血液中肿瘤-巨噬细胞融合细胞的PD-L1与转移性乳腺癌对PD-L1检查点抑制剂的应答相关 Monitoring PD-L1 in tumor macrophage fusion cells in blood correlates to PD-L1 checkpoint inhibitor responses in metastatic breast cancer Sonia Muthuraj, Massimo Cristofanilli, Carolina Reduzzi, Giuseppe Del Priore, William V. Williams, Cha-Mei Tang, Daniel L. Adams
• 1026 · PDF MYCL拷贝数扩增提示小细胞肺癌中血管生成的激活 The copy number amplification of MYCL indicated activation of angiogenesis in small cell lung cancer Zihang Yuan, Jingwei Zhang, Yan Ju, Xingyuan Wu, Mantang Qiu, Xiao Li
• 1027 · PDF 一种从组织病理切片计算得出的、可稳健预测晚期头颈部鳞状细胞癌免疫检查点抑制临床结局的标志物 A robust predictive marker of clinical outcomes to immune-checkpoint inhibition in advanced squamous head-and-neck cancer calculated from histopathological slides Yaron Kinar, Tien-Hua Chen, Gal Dinstag, Ranit Aharonov, Tuvik Beker, Johnathan Arnon, Anna Elia, Aron Popovtzer, Changsu Lawrence Park, Carlos Diego H. Lopes, Muh-Hwa Yang
• 1028 · PDF 一种肿瘤不可知的YAP/TAZ评分可独立于Hippo改变预测TEAD抑制剂敏感性 A tumor-agnostic YAP/TAZ score predicts TEAD inhibitor sensitivity independent of Hippo alterations Michael Wegert-Verhoeven, Mathea Fransisca, Sylvia Martin, Attila Jady, Daniela Richter, Malgorzata Oles, Timon A. Blindauer, Jan-Philipp Mallm, Jasmina Paluncic, Claudia Dagostino, Olga Ermakova, Annika Schneider, Matthew The, Annika Baude-Müller, Katja Beck, Maximilian Bullemer, Victor Didier Perez Meza, Vivek Venkataramani, Ralf C. Bargou, Heiko Becker, Melanie Boerries, Armin Tuchscherer, DKFZ/NCT/DKTK MASTER consortium, Martin Wermke, Andreas Brunschweiger, Mohammed Al-Saeedi, Dirk Jäger, Olaf Witt, Denis Schapiro, Bernhard Küster, Andreas Hartig, Michael Allgaeuer, Alexander Brobeil, Christoph E. Heilig, Maria Veronica Teleanu, Simon Kreutzfeldt, Peter Horak, Daniel Hübschmann, Wolfgang Hartmann, Marcel Trautmann, Ina Oehme, Claudia R. Ball, Stefan Fröhling, Stefan M. Pfister, Hanno Glimm, Sebastian M. Dieter

在会议检索中浏览本分会场